Highlighted transactions

Healthcare

 

Argenx SE

Piper Jaffray served as joint bookrunner on the $114.6 million IPO for argenx SE (Nasdaq: ARGX).

Client Description

argenx SE is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer.

Back